

University of Groningen

**Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein**

Corsetti, James P.; Sparks, Charles E.; James, Richard W.; Bakker, Stephan J. L.; Dullaart, Robin P. E.

*Published in:*  
Journal of Clinical Medicine

*DOI:*  
[10.3390/jcm8091357](https://doi.org/10.3390/jcm8091357)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Corsetti, J. P., Sparks, C. E., James, R. W., Bakker, S. J. L., & Dullaart, R. P. E. (2019). Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein. *Journal of Clinical Medicine*, 8(9), [1357]. <https://doi.org/10.3390/jcm8091357>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Article

# Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein

James P. Corsetti <sup>1,\*</sup>, Charles E. Sparks <sup>1</sup>, Richard W. James <sup>2</sup>, Stephan J. L. Bakker <sup>3</sup> and Robin P. F. Dullaart <sup>4</sup>

<sup>1</sup> Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 1211, USA

<sup>2</sup> Department of Medical Specialties-Endocrinology, Diabetology, Hypertension and Nutrition, University of Geneva, 1201 Geneva, Switzerland

<sup>3</sup> Department of Nephrology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands

<sup>4</sup> Department of Endocrinology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands

\* Correspondence: james\_corsetti@urmc.rochester.edu; Tel.: +1-585-275-4907; Fax: +1-585-273-3003

Received: 19 July 2019; Accepted: 27 August 2019; Published: 1 September 2019



**Abstract:** Paraoxonase-1 (PON1) is a key enzyme that inhibits low-density lipoprotein oxidation and consequently atherogenesis. Here, we assessed whether low serum PON1 activity associates with incident cardiovascular disease (CVD) in subjects with high levels of high-density cholesterol (HDL-C) and C-reactive protein (CRP), a marker of low-grade systemic inflammation. Cox proportional-hazards modeling of incident CVD risk (11 years mean follow-up) adjusted for relevant clinical and biomarker covariates was performed on a population-based study (N = 7766) stratified into three groups: low CRP—(LR; event rate 4.9%); low HDL-C/high CRP—(HR1; event rate 14.4%); and high HDL-C/high CRP—(HR2; event rate 7.6%). Modeling results for PON1 activity in HR2 were significant and robust (hazard ratio/SD unit—0.68, 95% CI 0.55–0.83,  $p = 0.0003$ ), but not so for LR and HR1. Analyses in HR2 of the interaction of PON1 with HDL-C, apoA-I, apoA-II, and apoE levels were significant only for PON1 with apoE (hazard ratio—1.77, 95% CI 1.29–2.41,  $p = 0.0003$ ). Subsequent subgroup analysis revealed inverse risk dependence for apoE at low PON1 levels. In conclusion, in a population-based study of subjects with concurrently high HDL-C and CRP levels, low serum PON1 activity associates with incident CVD risk with risk accentuated at low apoE levels.

**Keywords:** cardiovascular disease; C-reactive protein; HDL; paraoxonase-1

## 1. Introduction

Paraoxonases make up a family of three enzymes (PON1, PON2, and PON3) with predominantly lactonase activity, each of which has been shown to manifest anti-atherogenic properties. This presumably relates to hydrolytic activity against lactone-like structures elaborated by oxidized polyunsaturated fatty acids on lipoproteins [1,2]. PON2 is an intracellular enzyme. After synthesis in the liver, PON1 and PON3 enter the circulation and become predominantly associated with high-density lipoprotein (HDL) particles. Anti-atherogenic action of PON1 has been demonstrated to derive in large part from the interaction of HDL-associated PON1 with low-density lipoprotein (LDL) particles. Such interaction leads to inhibition of oxidative modification of LDL through PON1-mediated hydrolysis of oxidized fatty

acid species derived from oxidative stress-induced generation of hydroperoxides from phospholipids, cholesteryl esters, and triglycerides [2–6]. Likewise for HDL, studies have also demonstrated similar anti-oxidative activity by PON1 on lipid peroxidation products generated on HDL in oxidative stress environments [7–10]. The putative anti-atherogenic properties of PON1 stem from meta-analyses of human population studies that consistently show decreased PON1 activity to be associated with cardiovascular disease (CVD) risk [11–13]. It should also be noted that in addition to CVD, low PON1 activity has been reported in other disease states having a significant inflammatory component including diabetes mellitus, obesity, metabolic syndrome, cancer, and various rheumatic, renal, hepatic, and neurologic diseases [3,14].

Accumulating evidence demonstrates that the established anti-atherogenic actions of HDL become dysfunctional and potentially pro-atherogenic in chronic inflammatory and oxidative stress environments as a result of ensuing alterations in the HDL proteome and lipidome [15–17]. To elucidate the role of dysfunctional HDL in CVD risk, investigations of HDL-associated risk have been undertaken in populations with various inflammatory disorders. Notably, results from such studies demonstrate that high levels of HDL cholesterol (HDL-C) associate with increased CVD risk rather than with protective effects [18]. In our case, we have studied incident as well as recurrent coronary events in subjects with high HDL-C and concurrently high levels of C-reactive protein (CRP) as a marker of low-grade chronic inflammation. Compared to the controls, the results demonstrated significantly higher CVD risk in these patient groups [19,20]. Furthermore, within these populations, additional studies demonstrated risk associations for levels of apolipoprotein E (apoE) [21] and apolipoprotein A-II (apoA-II) [22]; and, in studies of single nucleotide polymorphisms, risk associations were found for genes associated with various aspects of HDL function including reverse cholesterol transport [19,23], thrombogenesis [24], oxidative stress [25], and fibrinolysis [26].

In light of the key role of PON1 in inhibiting oxidative changes in the HDL lipidome that acts to preserve anti-atherogenic functionality of HDL as described above, we hypothesized that low PON1 levels in subjects with high levels of HDL-C in the setting of chronic low-level inflammation would be at increased risk for CVD. To test this hypothesis, we studied risk of incident CVD in subjects having concurrently high HDL-C and CRP levels as an indicator of chronic low grade inflammation in comparison to two other subject groups, one with low HDL-C and high CRP levels and the other with “normal” HDL-C and low CRP levels. The present study was carried out in the frame of the prospective Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort study.

## 2. Experimental Section

### 2.1. Study Population

PREVEND, a large general population-based prospective cohort study begun in 1997 that aimed to explore the role of albuminuria in cardiovascular and renal disease, served as the basis of the current study population [27]. Briefly for PREVEND recruitment, all inhabitants of the city of Groningen, the Netherlands, aged 28–75 years ( $N = 85,421$ ), were sent a questionnaire requesting an early morning urine specimen. The response rate was 48% ( $N = 40,856$ ). Of these, 9966 subjects had urine albumin levels  $\geq 10$  mg/L while 30,890 subjects had urine albumin  $< 10$  mg/L. Exclusions included pregnancy, type 1 diabetic individuals, and type 2 diabetic individuals using insulin. This resulted in 7768 subjects having urine albumin  $\geq 10$  mg/L. This group was combined with 3395 randomly chosen subjects with urine albumin  $< 10$  mg/L. Of this resultant group, 8592 individuals completed an additional screening program, thus establishing the PREVEND study cohort. For the present work, the only further exclusion from the PREVEND study cohort was for subjects with serum CRP levels  $\geq 10$  mg/L. This formed the study population of the current work ( $N = 7766$ ). The PREVEND study was approved by the Medical Ethics Committee of the University of Groningen, the Netherlands. Informed written consent was obtained from all participants. The study adhered to the ethical principles set by the Declaration of Helsinki.

## 2.2. Clinical Parameters and Biomarkers

Questionnaires were used to ascertain cardiac history (hospitalization for myocardial infarction, revascularization procedures, or obstructive coronary artery disease). Diabetes was established either as fasting plasma glucose  $\geq 7.0$  mmol/L, self-report of physician diagnosis, or use of anti-diabetic medications. Medication use was retrieved via Groningen pharmacy dispensing data [28]. Smoking status was either current smoker or not; ethanol use was either one or less drinks per day or more than one drink per day (with one drink assumed to contain 10 g of alcohol). Body mass index (BMI) was calculated as weight divided by height squared ( $\text{kg/m}^2$ ). Blood pressure was measured for 10 min at 1-min intervals using automatic instrumentation (Dinamap XL Model 9300; Johnson-Johnson Medical, Tampa, FL, USA) in the supine position; means of the last two recordings were the reported values [29].

The mean of two 24 h collections over two consecutive days at study entry was determined and used as the reported UAE value. Nephelometry (BNII, Dade Behring, Marburg, Germany) was used to measure urinary albumin concentration. Blood biomarker levels at study initiation were performed on overnight-fasted plasma and sera. Blood levels of creatinine, HDL-C, apoA-I, apoA-II, apoE, total cholesterol, triglycerides, apoB, glucose, and CRP were determined by standard techniques [20,21,30]. Estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [31]. NonHDL-C was calculated as the difference between total cholesterol and HDL-C. The Friedewald equation was used to estimate LDL-C levels. Serum PON1 activity was measured in terms of arylesterase activity (rate of phenyl acetate hydrolysis to phenol) as described previously with inter-assay and intra-assay coefficients of variation of 8% and 6%, respectively [32].

## 2.3. Outcomes

CVD-related mortality and hospitalizations including acute MI (myocardial infarction), acute and subacute ischaemic heart disease, coronary artery bypass grafting, and percutaneous transluminal coronary angioplasty constituted incident cardiovascular events. Outcome events were followed over time (11 years of follow-up). Survival time was taken as date of initial urine collection (1997–1998) to date of first CVD event or to December 31, 2011. For subjects lost to follow-up (396 of the overall cohort of 8592 participants), censoring date was date of removal from the municipal registry. Record linkage with the Dutch Central Bureau of Statistics was used to acquire data on mortality and causes of death. PRISMANT, the Dutch national registry of hospital discharge diagnoses was used to obtain CVD morbidity data.


## 2.4. Data Analysis

Graphical and statistical analyses were performed using Statistica 13.3 (StatSoft, Inc., Tulsa, OK, USA). Graphical analyses portraying CVD risk over a bivariate parameter risk domain was performed using outcome event mapping as described previously [20]. Results are reported as means  $\pm$  SD for normally distributed variables and as medians (interquartile range) for non-normally distributed variables. Differences among groups were assessed by ANOVA for continuous variables using Bonferroni correction for multiple comparisons and chi-square testing for categorical variables. Non-normal variables were log-transformed for analyses. Multivariable Cox proportional hazards modeling was used to follow cardiovascular outcomes over time. Continuous independent variables were standardized by transformation to distributions with means of zero and standard deviations of one for Cox analyses. Hazard ratios (HR) are per SD unit. Inclusion of multiplicative interaction terms into base models was used to assess interactions between risk variables. Two-sided  $p$ -values  $< 0.05$  were considered statistically significant. The proportional hazards assumption was verified by correlation analysis of survival time with scaled Schoenfeld residuals.

### 3. Results

#### 3.1. Study Population

During follow-up (11 years), a total of 643 events were recorded. The surface plot of Figure 1A demonstrates the estimated CVD outcome event rate as a function of HDL-C rank and CRP rank for the resultant total study population. The figure shows two peaks indicative of higher-risk populations: one at low HDL-C and high CRP rank and one at high HDL-C and high CRP rank. The corresponding contour plot of Figure 1B demonstrates the delineation of three populations based upon dichotomizations about median values of HDL-C and CRP ranks. The three resulting populations were designated as follows: low CRP—low risk (LR;  $N = 3889$ ; 192 events; 4.9% event rate); low HDL-C/high CRP—high risk 1 (HR1;  $N = 2294$ ; 331 events; event rate 14.4%); and high HDL-C/high CRP—high-risk 2 (HR2;  $N = 1583$ ; 120 events; event rate 7.6%). Clinical and blood biomarker characterizations for the total, LR, HR1, and HR2 populations are given in Table 1. Results of chi square testing, unadjusted ANOVA, and ANOVA adjusted for gender and age revealed significant differences among the LR, HR1, and HR2 groups for all variables except ethanol use. Subsequent post-hoc testing revealed pair-wise significant differences between LR, HR1, and HR2 for all continuous variables except for: nonHDL-C (LR versus HR2,  $p = 0.078$ ), triglycerides (LR versus HR2,  $p = 0.90$ ), and UAE (LR versus HR2,  $p = 0.55$ ).



**Figure 1.** Cardiovascular event rates as a function of high-density lipoprotein (HDL) rank and C-reactive protein (CRP) rank given: (A) as a surface plot and (B) as a contour plot. The contour plot demarcates a low risk population (LR) characterized by lower CRP, a high-risk population (HR1) characterized by low HDL and high CRP, and another high-risk population (HR2) characterized by high HDL and high CRP.

**Table 1.** Clinical and biomarker parameters for the total study population and low risk (LR), high-risk 1 (HR1), and high-risk 2 (HR2) subpopulations. Biomarker levels are given as means  $\pm$  standard deviations for normally distributed parameters and medians with interquartile ranges for non-normally distributed parameters.

| Parameter                                     | Total Population | Low Risk (86.1% of Subjects) | High-Risk 1      | High-Risk 2      | <i>p</i> <sup>a</sup> | <i>p</i> <sup>b</sup> |
|-----------------------------------------------|------------------|------------------------------|------------------|------------------|-----------------------|-----------------------|
| Subjects N (%)                                | 7766             | 3889 (50.1)                  | 2294 (29.5)      | 1583 (20.4)      |                       |                       |
| Outcome events N (%)                          | 643 (8.3)        | 192 (4.9)                    | 331 (14.4)       | 120 (7.6)        | <0.001                |                       |
| Age (years)                                   | 49.1 $\pm$ 12.6  | 46.2 $\pm$ 11.8              | 52.8 $\pm$ 12.5  | 50.9 $\pm$ 13.2  | <0.001                |                       |
| Females (%)                                   | 50.1             | 49.0                         | 36.5             | 72.5             | <0.001                |                       |
| Cardiac history (%)                           | 4.4              | 2.5                          | 8.1              | 3.9              | <0.001                |                       |
| Diabetes (%)                                  | 3.2              | 1.4                          | 7.0              | 2.1              | <0.001                |                       |
| Metabolic Syndrome                            | 24.4             | 13.4                         | 51.3             | 9.7              | <0.001                |                       |
| Statins (%)                                   | 4.1              | 3.1                          | 6.3              | 3.3              | <0.001                |                       |
| Anti-hypertensives (%)                        | 13.6             | 8.4                          | 20.8             | 15.7             | <0.001                |                       |
| Current Smoker (%)                            | 33.3             | 27.7                         | 42.7             | 33.6             | <0.001                |                       |
| Ethanol Use (>1 drink/day %)                  | 25.3             | 25.9                         | 24.1             | 25.7             | 0.28                  |                       |
| Pulse Rate (per minute)                       | 69.0             | 68.7                         | 70.4             | 70.3             | <0.001                | <0.001                |
| Systolic BP (mmHg)                            | 129 $\pm$ 20     | 124 $\pm$ 18                 | 135 $\pm$ 21     | 131 $\pm$ 22     | <0.001                | <0.001                |
| Diastolic BP (mmHg)                           | 74 $\pm$ 10      | 72 $\pm$ 9                   | 77 $\pm$ 10      | 74 $\pm$ 10      | <0.001                | <0.001                |
| BMI (kg/m <sup>2</sup> )                      | 26.1 $\pm$ 4.2   | 24.6 $\pm$ 3.4               | 28.0 $\pm$ 4.3   | 26.2 $\pm$ 4.2   | <0.001                | <0.001                |
| HDL-C (mM)                                    | 1.32 $\pm$ 0.40  | 1.40 $\pm$ 0.41              | 1.01 $\pm$ 0.18  | 1.62 $\pm$ 0.29  | <0.001                | <0.001                |
| CRP (mg/L)                                    | 1.28 (0.56–2.98) | 0.54 (0.30–0.82)             | 2.76 (1.79–4.62) | 2.52 (1.71–4.16) | <0.001                | <0.001                |
| PON1 (U/L)                                    | 53.2 (43.2–65.1) | 53.7 (43.7–65.6)             | 50.8 (40.9–62.0) | 56.1 (46.6–68.3) | <0.001                | <0.001                |
| ApoA-I ( $\mu$ M)                             | 47.8 $\pm$ 9.9   | 48.0 $\pm$ 10.0              | 42.8 $\pm$ 6.8   | 54.7 $\pm$ 9.3   | <0.001                | <0.001                |
| ApoA-II ( $\mu$ M)                            | 19.6 $\pm$ 3.8   | 19.5 $\pm$ 3.8               | 18.7 $\pm$ 3.2   | 21.4 $\pm$ 4.0   | <0.001                | <0.001                |
| ApoA-I/HDL-C ( $\mu$ M/mM)                    | 37.8 $\pm$ 8.2   | 35.7 $\pm$ 7.7               | 43.2 $\pm$ 7.7   | 34.1 $\pm$ 5.1   | <0.001                | <0.001                |
| ApoA-II/HDL-C ( $\mu$ M/mM) ( $\mu$ mol/mmol) | 15.9 $\pm$ 4.6   | 14.8 $\pm$ 4.4               | 19.0 $\pm$ 4.1   | 13.4 $\pm$ 2.7   | <0.001                | <0.001                |
| Cholesterol (mM)                              | 5.65 $\pm$ 1.13  | 5.46 $\pm$ 1.08              | 5.88 $\pm$ 1.18  | 5.75 $\pm$ 1.11  | <0.001                | <0.001                |
| NonHDL-C (mM)                                 | 4.33 $\pm$ 1.21  | 4.05 $\pm$ 1.14              | 4.87 $\pm$ 1.19  | 4.13 $\pm$ 1.13  | <0.001                | <0.001                |
| LDL-C (mM)                                    | 3.69 $\pm$ 1.05  | 3.51 $\pm$ 0.99              | 4.04 $\pm$ 1.04  | 3.58 $\pm$ 1.05  | <0.001                | <0.001                |
| Triglycerides (mM)                            | 1.16 (0.85–1.68) | 1.00 (0.74–1.40)             | 1.59 (1.14–2.27) | 1.09 (0.83–1.42) | <0.001                | <0.001                |
| ApoB (g/L)                                    | 1.04 $\pm$ 0.30  | 0.96 $\pm$ 0.28              | 1.17 $\pm$ 0.32  | 1.01 $\pm$ 0.27  | <0.001                | <0.001                |
| Glucose (mM)                                  | 4.89 $\pm$ 1.19  | 4.67 $\pm$ 0.79              | 5.24 $\pm$ 1.58  | 4.76 $\pm$ 0.96  | <0.001                | <0.001                |
| Creatinine ( $\mu$ M)                         | 83.9 $\pm$ 19.5  | 83.1 $\pm$ 14.3              | 87.8 $\pm$ 26.3  | 80.7 $\pm$ 14.5  | <0.001                | <0.001                |
| UAE (mg/24 h)                                 | 9.5 (6.3–17.8)   | 8.4 (6.0–13.6)               | 11.8 (7.2–27.1)  | 9.4 (6.1–17.4)   | <0.001                | <0.001                |
| eGFR (mL/min/1.73 m <sup>2</sup> )            | 84.0 $\pm$ 15.6  | 86.5 $\pm$ 14.8              | 81.3 $\pm$ 16.1  | 81.5 $\pm$ 15.5  | <0.001                | <0.001                |
| ApoE ( $\mu$ M)                               | 1.15 $\pm$ 0.47  | 1.09 $\pm$ 0.42              | 1.26 $\pm$ 0.57  | 1.14 $\pm$ 0.39  | <0.001                | <0.001                |
| Paraoxonase/HDL-C (U/mM)                      | 41.7 (32.3–53.8) | 39.8 (30.7–50.7)             | 50.0 (40.5–63.8) | 35.0 (28.6–43.5) | <0.001                | <0.001                |
|                                               | 9                | 9                            | 9                | 9                |                       |                       |

<sup>a</sup> For categorical variables, chi-square results showed significant differences ( $p < 0.0001$ ) among the LR, HR1, and HR2 subgroups except for ethanol use ( $p = 0.28$ ); for continuous variables, unadjusted ANOVA revealed statistically significant differences ( $p < 0.0001$ ) among the subpopulations. Subsequent post-hoc testing revealed significant differences ( $p < 0.0001$ ) between populations for all parameters except for cholesterol (HR1 versus HR2,  $p = 0.0018$ ), LDL-C (LR versus HR1,  $i = 0.035$ ), glucose (LR versus HR1,  $p = 0.017$ ), and apoE (LR versus HR1,  $p = 0.0012$ ) and non-significant results for nonHDL-C (LR versus HR2,  $p = 0.078$ ), triglycerides (LR versus HR2,  $p = 0.90$ ), and UAE (LR versus HR2,  $p = 0.55$ ). <sup>b</sup> ANOVA adjusted for age and gender also revealed statistically significant differences ( $p < 0.0001$ ) among the subpopulations. BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; CRP, C-reactive protein; PON1, Paraoxonase-1; ApoA-I, apolipoprotein A-I; ApoA-II, apolipoprotein A-II; NonHDL-C, non-HDL lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoB, apolipoprotein B; ApoE, apolipoprotein E; UAE, urinary albumin excretion; eGFR, estimated glomerular filtration rate.



### 3.2. Correlation of PON1 Activity with Blood Biomarker Levels

To provide further characterization of the study populations focusing on PON1 activity, Table 2 gives Spearman correlation coefficients for PON1 activity levels with blood biomarkers for the total, LR, HR1, and HR2 populations. The table shows that although many of the correlations are statistically significant, magnitudes of the coefficients are generally small except for HDL-C, apoA-I, and apoA-II (highest at 0.28). Thus, PON1 activity did not appear to be highly correlated with any of the blood biomarkers in any of the populations which may be indicative potentially of a relatively independent role of PON1 activity in CVD risk.

**Table 2.** Spearman correlation coefficients of PON1 with biomarker levels for total, LR, HR1, and HR2 populations.

| Parameter                 | Total Population | Low Risk  | High-Risk 1 | High-Risk 2 |
|---------------------------|------------------|-----------|-------------|-------------|
| HDL-C                     | 0.20 ***         | 0.19 ***  | 0.11 ***    | 0.15 ***    |
| CRP                       | −0.05 ***        | −0.02     | −0.06 **    | 0.02        |
| ApoA-I                    | 0.19 ***         | 0.17 ***  | 0.10 ***    | 0.15 ***    |
| ApoA-II                   | 0.28 ***         | 0.26 ***  | 0.23 ***    | 0.26 ***    |
| ApoA-I/HDL-C              | −0.12 ***        | −0.11 *** | −0.04       | 0.01        |
| ApoA-II/HDL-C (μmol/mmol) | −0.04 ***        | −0.03     | 0.08 ***    | 0.13 ***    |
| Cholesterol               | 0.08 ***         | 0.13 ***  | 0.09 ***    | 0.01        |
| NonHDL-C                  | 0.01             | 0.05 **   | 0.07 **     | −0.03       |
| LDL-C                     | 0.00             | 0.04 *    | 0.04        | −0.06 *     |
| Triglycerides             | 0.03 *           | 0.03 *    | 0.09 ***    | 0.13 ***    |
| ApoB                      | 0.00             | 0.03      | 0.05 *      | −0.02       |
| Glucose                   | −0.09 ***        | −0.09 *** | −0.05 *     | −0.07 **    |
| Creatinine                | −0.03 **         | 0.01      | −0.04       | −0.02       |
| UAE                       | −0.02            | 0.02      | −0.01       | 0.01        |
| eGFR                      | 0.02 *           | −0.01     | 0.05 *      | 0.03        |
| ApoE                      | 0.00             | 0.04 *    | 0.04        | −0.07 **    |

\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

### 3.3. PON1 Activity as a Marker of CVD Risk in LR, HR1, and HR2 Populations

To assess PON1 activity as a marker of CVD risk, Table 3 gives results of Cox multivariable proportional hazards modeling in the three populations. For the LR population, PON1 activity was significant (protective) in an unadjusted model, but lost significance upon adjustment for gender and age. For HR1, PON1 activity, even in an unadjusted model, did not achieve significance. For HR2, PON1 activity was highly significant (protective) in an unadjusted model ( $p = 10^{-6}$ ); continued to be highly significant in a collection of models adjusted for gender, age, and a set of covariates added one-at-time; and finally remained significant ( $p = 0.0003$ ) in a model adjusted simultaneously for all covariates of the dataset (gender, age, UAE, past CVD, DM, apoB, use of statins, anti-hypertensives, smoking, ethanol use, and eGFR). Thus, PON1 activity appears to have a robust inverse relationship with CVD risk in the HR2 population.

**Table 3.** Cox multivariable proportional hazards modeling results for PON1 level giving hazard ratio (HR), 95% confidence interval (95% CI), and *p*-value. The first column lists the population examined (LR, HR1, or HR2) along with parameters adjusted in models. Hazard ratios are per SD unit. For regression calculations, PON1 levels were transformed to a distribution with mean of zero and SD of one.

| Population | Model Adjustments                                                                                       | HR   | 95% CI<br>(86.1% of Subjects) | <i>p</i> -Value |
|------------|---------------------------------------------------------------------------------------------------------|------|-------------------------------|-----------------|
| LR         | unadjusted                                                                                              | 0.86 | 0.75–0.98                     | 0.024           |
| LR         | gender, age                                                                                             | 0.95 | 0.82–1.09                     | 0.46            |
| HR1        | unadjusted                                                                                              | 0.93 | 0.83–1.04                     | 0.22            |
| HR1        | gender, age                                                                                             | 1.02 | 0.91–1.14                     | 0.72            |
| HR2        | unadjusted                                                                                              | 0.62 | 0.000001                      | 0.000001        |
| HR2        | gender, age                                                                                             | 0.72 | 0.59–0.87                     | 0.0007          |
| HR2        | gender, age, UAE                                                                                        | 0.70 | 0.58–0.86                     | 0.0004          |
| HR2        | gender, age, UAE, apoB                                                                                  | 0.70 | 0.57–0.85                     | 0.0003          |
| HR2        | gender, age, UAE, past CVD                                                                              | 0.71 | 0.58–0.86                     | 0.0005          |
| HR2        | gender, age, UAE, DM                                                                                    | 0.71 | 0.58–0.86                     | 0.0006          |
| HR2        | gender, age, UAE, statins                                                                               | 0.69 | 0.57–0.83                     | 0.0002          |
| HR2        | gender, age, UAE, anti-hypertensives                                                                    | 0.68 | 0.56–0.83                     | 0.0001          |
| HR2        | gender, age, UAE, SBP                                                                                   | 0.70 | 0.58–0.85                     | 0.0004          |
| HR2        | gender, age, UAE, DBP                                                                                   | 0.70 | 0.58–0.85                     | 0.0004          |
| HR2        | gender, age, UAE, smoking                                                                               | 0.70 | 0.58–0.85                     | 0.0004          |
| HR2        | gender, age, UAE, ethanol use                                                                           | 0.69 | 0.57–0.84                     | 0.0003          |
| HR2        | gender, age, UAE, eGFR                                                                                  | 0.72 | 0.59–0.87                     | 0.0009          |
| HR2        | gender, age, UAE, past CVD, DM, apoB, statins, anti-hypertensives, smoking, ethanol use, eGFR, SBP, DBP | 0.68 | 0.55–0.83                     | 0.0003          |

### 3.4. HDL Particle Constituents in Addition to PON1 as Markers of CVD Risk in HR2


To assess HDL-associated markers of risk in HR2 beyond PON1, we determined proportional hazards modeling in HR2 as a function of PON1 activity along with additional single entry of HDL-associated parameters (apoA-I, apoA-II, apoA-I/HDL-C, apoA-II/HDL-C, and apoE levels) (Table 4). Models also included evaluation of the potential interaction of PON1 activity with each of the HDL-associated parameters. Again, all models were adjusted for gender, age, UAE, past CVD, DM, apoB, use of statins, anti-hypertensives, smoking, ethanol use, eGFR, SBP, and DBP. The results from Table 4 indicate that, in each case for models without interaction, an independent significant protective association continued for PON1. For HDL-associated parameters, an independent protective association was demonstrated for apoA-I/HDL-C. In models assessing interactions, only apoE levels were found to exhibit a statistically significant interaction with PON1 activity (HR−1.77, 95% CI 1.29–2.41, *p* = 0.0003).

To explore the nature of the PON1/apoE interaction in HR2, subgroup analysis using the proportional hazards model adjusted as before was performed on subjects of HR2 but this time with dichotomization about median PON1 levels giving low- and high-PON1 groups. Results indicated a trend in continued risk association with low PON1 levels both in the low PON1 group (HR−0.74, 95% CI 0.53–1.05, *p* = 0.089) and the high PON1 group (HR−0.60, 95% CI 0.26–1.40, *p* = 0.24). Regarding apoE and risk, while results for the high PON1 group demonstrated the generally expected trend in risk associated with high apoE levels (HR−1.41, 95% CI 0.91–2.18, *p* = 0.13), results for the low PON1 group revealed significant risk in association with low apoE levels (HR−0.69, 95% CI 0.50–0.96, *p* = 0.029). To illustrate the interaction, a contour plot of estimated CVD risk as a function of PON1 rank and apoE rank was generated (Figure 2). Consistent with the modeling results, the plot shows a high-risk population at concurrently low levels of both PON1 and apoE; while by contrast, at high PON1 levels, there is little indication of risk in association with low apoE levels. Hence in HR2, it would appear that the PON1/apoE interaction manifests as intensification of the usual CVD risk association for low PON1 activity but particularly in the setting of low apoE levels.



**Table 4.** Interaction of PON1 with HDL-related parameters for the HR2 population as assessed by Cox proportional hazards models of cardiovascular event occurrence adjusted for gender, age, UAE, past CVD history, diabetes, apoB, statin use, anti-hypertensive use, smoking, ethanol use, eGFR, SBP, and DBP. Hazard ratios are per SD unit. For regression calculations, continuous variables were transformed to distributions with means of zero and SDs of one.

| Parameters    | Models without Interaction |           |          | Models with Interaction |            |          |
|---------------|----------------------------|-----------|----------|-------------------------|------------|----------|
|               | HR                         | 95% CI    | <i>p</i> | HR                      | 95% CI     | <i>p</i> |
| PON1          | 0.67                       | 0.54–0.83 | 0.0003   | 0.76                    | 0.57–1.01  | 0.059    |
| HDL-C         | 1.04                       | 0.75–1.45 | 0.82     | 1.01                    | 0.72–1.40  | 0.98     |
| interaction   |                            |           |          | 0.81                    | 0.057–1.16 | 0.25     |
| PON1          | 0.69                       | 0.56–0.86 | 0.0007   | 0.69                    | 0.54–0.89  | 0.0036   |
| ApoA-I        | 0.76                       | 0.58–1.00 | 0.051    | 0.76                    | 0.58–1.00  | 0.054    |
| interaction   |                            |           |          | 0.99                    | 0.77–1.29  | 0.96     |
| PON1          | 0.70                       | 0.57–0.88 | 0.002    | 0.70                    | 0.57–0.87  | 0.001    |
| ApoA-II       | 0.78                       | 0.60–1.02 | 0.070    | 0.79                    | 0.61–1.02  | 0.070    |
| interaction   |                            |           |          | 1.09                    | 0.90–1.31  | 0.39     |
| PON1          | 0.66                       | 0.54–0.82 | 0.0001   | 0.71                    | 0.55–0.92  | 0.008    |
| ApoA-I/HDL-C  | 0.56                       | 0.37–0.85 | 0.0057   | 0.59                    | 0.39–0.89  | 0.013    |
| interaction   |                            |           |          | 1.17                    | 0.87–1.57  | 0.30     |
| PON1          | 0.68                       | 0.55–0.84 | 0.0004   | 0.81                    | 0.60–1.08  | 0.15     |
| ApoA-II/HDL-C | 0.63                       | 0.40–1.00 | 0.051    | 0.65                    | 0.41–1.03  | 0.065    |
| interaction   |                            |           |          | 1.30                    | 0.94–1.80  | 0.12     |
| PON1          | 0.66                       | 0.53–0.82 | 0.0002   | 0.64                    | 0.51–0.80  | 0.0001   |
| ApoE          | 0.82                       | 0.60–1.12 | 0.21     | 0.85                    | 0.62–1.16  | 0.30     |
| interaction   |                            |           |          | 1.77                    | 1.29–2.41  | 0.0003   |



**Figure 2.** Contour plot of the estimated cardiac event rate as a function of PON1 rank and apoE rank in the high HDL/high CRP population (HR2).

#### 4. Discussion

Results of the current study of incident CVD show a highly significant association of low serum PON1 activity with risk in subjects with high levels of HDL-C in the setting of chronic low-grade inflammation, as indicated by high CRP levels. Furthermore, interaction analysis demonstrated such risk to be accentuated in those subjects with low levels of serum apoE; no corresponding effect was observed for apoA-I, apoA-II, or HDL-C levels within the high HDL-C/high CRP group. These results from multivariable proportional hazards modeling were robust with regard to adjustment for relevant clinical and blood biomarkers including gender, age, past CVD event, diabetes, apoB, statin use, anti-hypertensive use, smoking, ethanol use, and eGFR. It should be noted that corresponding analyses

performed both on subjects with low HDL-C and high CRP and on subjects with low CRP did not demonstrate in either case statistically significant associations for PON1 activity with CVD. Our results suggest that the putative anti-oxidative effects of serum PON1 are most evidently exhibited in subjects with high PON1 and high HDL-C levels in the setting of chronic inflammation that is signaled by higher CRP levels.

Results of a recent meta-analysis addressing the role of PON1 activity on incident CVD risk demonstrated an inverse relationship between PON1 activity and risk in general population settings [13]. It was also noted in this study that the inverse relationship became less robust when adjustments for established risk factors including HDL-C were included—a finding that could potentially be relevant to our results regarding PON1 activity in the high HDL-C/high CRP group. However, this does not appear to be the case as results of risk models including PON1 activity and HDL-C levels were not significant for HDL-C ( $p = 0.82$ ); nor was interaction between the two significant ( $p = 0.25$ ). It should also be noted that corresponding analyses of PON1 activity with apoA-I and apoA-II were also non-significant. Accordingly, although study results show a significant inverse relationship for PON1 activity with risk, this is not the case for other HDL parameters including levels of HDL-C, apoA-I, and apoA-II. These findings underscore the key role of low PON1 activity in establishment of CVD risk in this subject group, which likely derives from inhibition of oxidative modification of the HDL lipidome, thus helping to maintain HDL anti-atherogenic functionality. Consistent with our results regarding low PON1 activity in the high HDL-C/high CRP subgroup, as noted previously, many other disease states associated with low-grade chronic inflammation also manifest low PON1 activity [3,14]. In the case of CVD risk, in the current study we have identified a group of subjects where PON1 action is particularly relevant.

Further results from our study did not show association of PON1 activity with risk both in the low risk subject group (low CRP levels) and in a subject group with low HDL-C/high CRP levels. In the first case, we speculate that the lower CRP levels provide an environment not conducive to oxidative modification of HDL, thus preserving HDL functionality and consequently limiting the relevance of PON1 activity in this group. In the second case, we speculate that higher PON1 was not protective in HR1 stemming in one way or another from the inadequacy of PON1 to significantly inhibit oxidation of the presumably heavier load of small dense LDL particles very likely present in this population enriched with Metabolic Syndrome subjects (Table 1; HR1—51.3%, HR2—9.7%,  $p < 0.001$ ). Inadequacy of PON1 in this setting is likely attributable to multiple factors. First, the load of LDL-C in HR1 was significantly higher than in HR2 (Table 1; 4.04 mM U/L versus 3.58 mM U/L,  $p < 0.001$ ); and thus, the concentration of potentially atherogenic dense LDL particles would be higher in HR1 given their well-established smaller size. Second, from the very defining characteristics of HR1, the level of HDL-C was less than in HR2 (Table 1; 1.01 mM versus 1.62 mM,  $p < 0.001$ ). Thus, the amount of PON1, known to be predominantly carried by HDL, should be and was observed to be smaller in HR1 (Table 1; 50.8 U/L versus 56.1 U/L,  $p < 0.001$ ). Third, the carriage ability of HDL particles for PON1 might be less in HR1 versus HR2 subjects. Thus, using the apoA-I/HDL-C ratio as a crude measure of the number of apoA-I molecules per HDL particle, the observed higher apoA-I/HDL-C ratio in HR1 versus HR2 (Table 1, 43.2  $\mu\text{M}/\text{mM}$  versus 34.1  $\mu\text{M}/\text{mM}$ ,  $p < 0.001$ ) would tend to limit carriage of additional molecules like PON1 on HDL particles (the situation was similar for the apoA-II/HDL-C ratio).

Additional results in the high HDL-C/high CRP group of our study using interaction analysis showed accentuation of CVD risk at concurrently low levels of PON1 and apoE. This is consistent with in vitro studies of PON1 associations with reconstituted HDL particles carrying apoE that show such binding to stabilize and stimulate PON1 lactonase activity as well as to stimulate PON1 anti-atherogenic potential in a manner similar to apoA-I but with lower capacity [33]. Presumably then, lower apoE levels would work to decrease PON1 anti-atherogenic action. Furthermore, results of a clinical study of metabolic syndrome (MetS) showed that although subjects without MetS demonstrated a positive correlation of PON1 activity with serum apoE levels, suggestive of enhancement of PON1 anti-atherogenic action with increased apoE levels; the relationship was abrogated in subjects with MetS, a condition associated with inflammation and oxidative stress [34].

There were strengths and limitations in our study. Strengths included the availability of a large well-characterized population-based study cohort followed prospectively for CVD outcomes for an average of 11 years and availability of extensive corresponding clinical and laboratory parameters including serum apoA-I, apoA-II, and apoE levels. The study was limited in a number of ways. In terms of the study population, there were exclusions for pregnancy, and type 1 diabetes mellitus and for subjects with serum CRP  $\geq 10$  mg/L (to minimize confounding effects by acute inflammation, rheumatic or other disease conditions manifesting high levels of inflammation); while it should also be noted that the study cohort was almost exclusively comprised of subjects of white European origin thus potentially limiting relevance of study findings to other populations. Additionally, the study population was enriched with albuminuric subjects; however, risk modeling results included adjustments for UAE and eGFR to account for this. In terms of clinical and laboratory parameters, values were determined only at study initiation, thus limiting the effects of parameter value variation over time. Regarding PON1 action, arylesterase activity as a measure was chosen because of good assay precision and good correlation with PON1 mass assays [35]. Lastly, there was no experimental evidence to verify that the HDL lipidome was actually preserved from oxidative dysfunctional transformation by high PON1 activity as speculated in our study. Poor performance of the technically difficult characterization of lipoprotein lipidomics might determine the effect of *PON1* on the risk of functional genetic polymorphisms.

In summary, the results of our current work show that low serum PON1 activity is associated with increased CVD risk in a group of subjects from a population-based study having concurrently high levels of HDL-C and CRP indicative of a chronic low-grade inflammatory environment. We believe that high serum PON1 activity in this group serves to facilitate inhibition of oxidative modification of the HDL lipidome, thus tending to preserve anti-atherogenic functionality of HDL particles including the curtailing of LDL oxidation. As such, these findings serve to underscore the presumptive efficacy of PON1 activity in the inhibition of lipoprotein oxidative modification.

## 5. Conclusion

Individuals having high HDL-C levels in the setting of chronic systemic inflammation have increased risk for incident cardiovascular disease. Furthermore, in such individuals, low serum PON1 levels associate with risk with risk accentuated at low apoE levels."

**Author Contributions:** The authors' responsibilities were as follows: R.W.J. performed the PON-1 activity measurements. J.P.C. analyzed data/performed statistical analysis; J.P.C., C.E.S., R.W.J., S.J.L.B., and R.P.F.D. interpreted the data analysis; J.P.C. and R.P.F.D. wrote the paper; J.P.C. and R.P.F.D. had primary responsibility for final content. All authors read and approved the final manuscript.

**Funding:** The research was funded by the Dutch Kidney Foundation (Grant E.033) and the Dutch Heart Foundation (Grant 2001-005).

**Acknowledgments:** The PON-1 activity measurements were performed in the laboratory of James, University of Geneva, Switzerland.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Reddy, S.T.; Devarajan, A.; Bourquard, N.; Shih, D.; Fogelman, A.M. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? *Curr. Opin. Lipidol.* **2008**, *19*, 405–408. [[CrossRef](#)] [[PubMed](#)]
2. Chistiakov, D.A.; Melnichenko, A.A.; Orekhov, A.N.; Bobryshev, Y.V. Paraoxonase and atherosclerosis-related cardiovascular diseases. *Biochimie* **2017**, *132*, 19–27. [[CrossRef](#)] [[PubMed](#)]
3. Mackness, M.; Mackness, B. Human paraoxonase-1 (*PON1*); Gene structure and expression, promiscuous activities and multiple physiological roles. *Gene* **2015**, *567*, 12–21. [[CrossRef](#)] [[PubMed](#)]
4. Manolescu, B.N.; Busu, C.; Badita, D.; Stanculescu, R.; Berteanu, M. Paraoxase 1—an update of the antioxidant properties of high-density lipoproteins. *Medica J. Clin. Med.* **2015**, *10*, 173–177.

5. Kowalska, K.; Socha, E.; Milerowicz, H. The role of paraoxonase in cardiovascular disease. *Ann. Clin. Lab. Sci.* **2015**, *45*, 226–233. [[PubMed](#)]
6. Shunmoogam, N.; Naidoo, P.; Chilton, R. Paraoxonase (PON1): A brief overview on genetics, structure, polymorphisms and clinical relevance. *Vasc. Health Risk Manag.* **2018**, *14*, 137–143. [[CrossRef](#)]
7. Aviram, M.; Rosenblat, M.; Bisgaier, C.L.; Newton, R.S.; Primo-Parmo, S.L.; La Du, B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. *J. Clin. Investig.* **1998**, *101*, 1581–1590. [[CrossRef](#)]
8. Ahmed, Z.; Ravandi, A.; Maguire, G.F.; Emili, A.; Draganow, D.; La Du, B.N.; Kuksis, A.; Connelly, P.W. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. *J. Biol. Chem.* **2001**, *276*, 24473–24481. [[CrossRef](#)]
9. Mackness, M.; Durrington, P.; Mackness, B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. *Curr. Opin. Lipidol.* **2004**, *15*, 399–404. [[CrossRef](#)]
10. Mastorikou, M.; Mackness, M.; Mackness, B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. *Diabetes* **2006**, *55*, 3099–3103. [[CrossRef](#)]
11. Zhao, Y.; Ma, Y.; Fang, Y.; Liu, L.; Wu, S.; Fu, D.; Wang, X. Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. *Mol. Genet. Metab.* **2012**, *105*, 141–148. [[CrossRef](#)] [[PubMed](#)]
12. Wang, M.; Lang, X.; Cui, S.; Zou, L.; Cao, J.; Wang, S.; Wu, X. Quantitative assessment of the influence of paraoxonase activity and coronary heart disease risk. *DNA Cell Biol.* **2012**, *31*, 975–982. [[CrossRef](#)] [[PubMed](#)]
13. Kunutsor, S.K.; Bakker, S.J.L.; James, R.W.; Dullaart, R.P.F. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. *Atherosclerosis* **2016**, *245*, 143–154. [[CrossRef](#)] [[PubMed](#)]
14. Goswami, B.; Tayal, D.; Gupta, N.; Mallika, V. Paraoxonase: A multifaceted biomolecule. *Clin. Chem. Acta* **2009**, *410*, 1–12. [[CrossRef](#)] [[PubMed](#)]
15. Rosenson, R.S.; Brewer, H.B.; Ansell, B.J.; Barter, P.; Chapman, M.J.; Heinecke, J.W.; Kontush, A.; Tall, A.R.; Webb, N.R. Dysfunctional HDL and atherosclerotic cardiovascular disease. *Nat. Rev. Cardiol.* **2016**, *13*, 48–60. [[CrossRef](#)] [[PubMed](#)]
16. Annema, W.; von Eckardstein, A. Dysfunctional high-density lipoproteins in coronary heart disease: Implications for diagnostics and therapy. *Transl. Res.* **2016**, *173*, 30–57. [[CrossRef](#)] [[PubMed](#)]
17. Srivastava, R.A.K. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. *Mol. Cell Biochem.* **2018**, *440*, 167–187. [[CrossRef](#)]
18. Chang, T.I.; Streja, E.; Moradi, H. Could high-density lipoprotein cholesterol predict increased cardiovascular risk? *Curr. Opin. Endocrinol. Diabetes Obes.* **2017**, *24*, 140–147. [[CrossRef](#)]
19. Corsetti, J.P.; Ryan, D.; Rainwater, D.L.; Moss, A.J.; Zareba, W.; Sparks, C.E. Cholesteryl Ester Transfer Protein Polymorphism (TaqIB) Associates with Risk in Postinfarction Patients with High C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels. *Atheroscler. Thromb. Vasc. Biol.* **2010**, *30*, 1657–1664. [[CrossRef](#)]
20. Corsetti, J.P.; Gansevoort, R.T.; Sparks, C.E.; Dullaart, R.P.F. Inflammation reduces HDL protection against primary cardiac risk. *Eur. J. Clin. Investig.* **2010**, *40*, 483–489. [[CrossRef](#)]
21. Corsetti, J.P.; Gansevoort, R.T.; Bakker, S.J.L.; Navis, G.J.; Sparks, C.E.; Dullaart, R.P.F. Apolipoprotein E Predicts Incident Cardiovascular Disease Risk in Women but not in Men with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein. *Metab. Clin. Exp.* **2012**, *61*, 996–1002. [[CrossRef](#)] [[PubMed](#)]
22. Corsetti, J.P.; Bakker, S.J.L.; Sparks, C.E.; Dullaart, R.P.F. Apolipoprotein A-II Influences Apolipoprotein E-Linked Cardiovascular Disease Risk in Women with High Levels of HDL Cholesterol and C-Reactive Protein. *PLoS ONE* **2012**, *7*, e39110. [[CrossRef](#)] [[PubMed](#)]
23. Corsetti, J.P.; Gansevoort, R.T.; Navis, G.J.; Sparks, C.E.; Dullaart, R.P.F. LPL Polymorphism (D9N) Predicts Cardiovascular Disease Risk Directly and Through Interaction with CETP Polymorphism (TaqIB) in Women with High HDL Cholesterol and CRP. *Atherosclerosis* **2011**, *214*, 373–376. [[CrossRef](#)] [[PubMed](#)]
24. Corsetti, J.P.; Ryan, D.; Moss, A.J.; McCarthy, J.J.; Goldenberg, I.; Zareba, W.; Sparks, C.E. Thrombospondin-4 Polymorphism (A387P) Predicts Cardiovascular Risk in Postinfarction Patients with High HDL Cholesterol and C-Reactive Protein Levels. *Thromb. Haemost.* **2011**, *106*, 1170–1178. [[PubMed](#)]

25. Le, N.T.; Corsetti, J.P.; Dehoff-Sparks, J.L.; Sparks, C.E.; Fujiwara, K.; Abe, J.I. Reactive Oxygen Species (ROS), SUMOylation, and Endothelial Inflammation. *Int. J. Inflamm.* **2012**, *2012*, 678190. [[CrossRef](#)] [[PubMed](#)]
26. Corsetti, J.P.; Salzman, P.; Ryan, D.; Moss, A.J.; Zareba, W.; Sparks, C.E. Plasminogen Activator Inhibitor-2 Polymorphism Associates with Recurrent Coronary Event Risk in Patients with High HDL and C-Reactive Protein Levels. *PLoS ONE* **2013**, *8*, e68920. [[CrossRef](#)] [[PubMed](#)]
27. Pinto-Sietsma, S.J.; Janssen, W.M.; Hillege, H.L.; Navis, G.; De Zeeuw, D.; De Jong, P.E. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. *J. Am. Soc. Nephrol.* **2000**, *11*, 1882–1888.
28. Kappelle, P.J.W.H.; Gansevoort, R.T.; Hillege, J.L.; Wolffenbuttel, B.H.R.; Dullaart, R.P.F. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. *J. Intern. Med.* **2011**, *269*, 232–242. [[CrossRef](#)]
29. De Greeff, A.; Reggiori, F.; Shennan, A.H. Clinical assessment of the DINAMAP ProCare monitor in an adult population according to the British Hypertension Society Protocol. *Blood Press. Monit.* **2007**, *12*, 51–55. [[CrossRef](#)]
30. Borggreve, S.E.; Hillege, H.L.; Wolffenbuttel, B.H.R.; de Jong, P.E.; Zuurman, M.W.; van der Steege, G.; van Tol, A.; Dullaart, R.P.F.; PREVEND Study Group. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: A population-based study. *J. Clin. Endocrinol. Metab.* **2006**, *91*, 3382–3388. [[CrossRef](#)]
31. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F.; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. *Ann. Intern. Med.* **2009**, *150*, 604–612. [[CrossRef](#)] [[PubMed](#)]
32. Van den Berg, E.H.; Gruppen, E.G.; James, R.W.; Bakker, S.J.L.; Dullaart, R.P.F. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. *J. Lipid Res.* **2019**, *60*, 168–175. [[CrossRef](#)] [[PubMed](#)]
33. Gaidukov, L.; Viji, R.I.; Jacobson, S.; Rosenblat, M.; Aviram, M.; Tawfik, D.S. ApoE induces serum paraoxonase PON1 activity and stability similar to apoA-I. *Biochemistry* **2010**, *49*, 532–538. [[CrossRef](#)] [[PubMed](#)]
34. Dullaart, R.P.F.; Kwakernaak, A.J.; Dallinga-Thie, G.M. The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. *Atherosclerosis* **2013**, *230*, 6–11. [[CrossRef](#)] [[PubMed](#)]
35. Dullaart, R.P.F.; Otvos, J.D.; James, R.W. Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects. *Clin. Biochem.* **2014**, *47*, 1022–1027. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).